CDKN2C

Across TCGA pan-cancer cohorts, CDKN2C RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of CDKN2C’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CDKN2C RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CDKN2C is over-expressed in tumor, although a few such as BRCA and UCEC show the opposite, repressed pattern.

KIRC, LIHC, and KIRP are the cancer types where CDKN2C tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CDKN2C RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	III,IV	+1.993	<.001	12	view →
LIHC	Female	II,III,IV	+2.417	<.001	9	view →
KIRP	Female	All	+1.623	<.001	8	view →
BRCA	All	III,IV	−1.122	<.001	6	view →
LUSC	All	All	+0.722	<.001	5	view →
LUAD	Male	All	+0.674	<.001	5	view →
BLCA	Female	IV	+2.126	.020	4	view →
UCEC	All	All	−1.408	<.001	4	view →
CHOL	All	All	+1.947	<.001	3	view →
KICH	Female	All	−1.073	<.001	3	view →
COAD	All	IV	−0.548	.028	2	view →
STAD	All	All	+0.487	.017	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

CDKN2C–KIRC

Open the KIRC breakdown →